1. Heron M. Deaths: Leading Causes for 2013. National Vital Statistics Reports. Volume 65, Number 2. (PHS) 2016.
2. Rosenberg SR, Kallan R, Mannino DM. Epidemiology of Chronic Obstructive Pulmonary Disease: Prevalence, Morbidity, Mortality, and Risk Factors. Semin Respir Crit Care Med. 2015 Aug;36(4):457-69.
3. Prevention of COPD. Available from: http://www.goldcopd.org, Accessed January 29, 2013.
4. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-28.
5. Press VG, Konetzka RT, White SR. Insights about the economic impact of COPD readmissions post implementation of the Hospital Readmission Reduction Program. Curr Opin Pulm Med 2018 Mar, 24(2): 138-146.
6. Palli SR, Buikema AR, DuCharme M, Frazer M, Kaila S, Juday T. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease. JCER. 2019, 8(15):1299-1316.
7. Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J. Evaluation of real-world health care resource utilization (HCRU) among patients with COPD initiating combination tiotropium/olodaterole versus triple therapy. ePoster presented at American Thoracic Society Annual Conference, 2020.

The authors wish to thank Sharanya Murali, MS for project management services.

This study was funded by Boehringer Ingelheim Pharmaceuticals, Inc. The author(s) meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no direct compensation related to the development of the poster. Writing, editorial support, and formatting assistance for this poster was provided by Yvette Greiner, MS of Optum, which was contracted and compensated by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), for these services. BIPI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations.